FibroBiologics annual meeting approves 2026 equity plan, re-elects director

FibroBiologics, Inc.

Stockholders approved the 2026 Equity and Incentive Plan with 2.62M for, 297k against; 2.06M shares available, including 2M new shares and 61,968 from prior plan.
Pete O'Heeron re-elected as Class III director with 2.80M for, 119k against; Stacy Coen did not stand for re-election.
Ratified WithumSmith+Brown as auditor for FY 2026 with 4.11M for, 43k against.
Approved issuance of up to 2.27M shares from March SPA warrants and 159k shares from H.C. Wainwright engagement letter.
4.17M shares represented out of 6.83M eligible; all four proposals passed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.